


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

**ANNOUNCEMENT PURSUANT TO RULE 13.18 OF THE LISTING RULES
FACILITY AGREEMENT WITH SPECIFIC PERFORMANCE COVENANTS**

This announcement is made by Sino Biopharmaceutical Limited (the “**Company**”) pursuant to Rule 13.18 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

FACILITY AGREEMENT

On 1 December 2021, the Company as borrower entered into a facility agreement (the “**Facility Agreement**”) with, among others, Bank of China (Hong Kong) Limited, BNP Paribas, Citigroup Global Markets Asia Limited, The Hongkong and Shanghai Banking Corporation Limited, Bank of Communications (Hong Kong) Limited, China Merchants Bank Co., Ltd., Hong Kong Branch, Hang Seng Bank, Limited, and Industrial and Commercial Bank of China (Asia) Limited as mandated lead arrangers and bookrunners pursuant to which certain senior term loan and revolving credit facilities in an aggregate amount of US\$1,000,000,000 has been granted to the Company.

SPECIFIC PERFORMANCE OBLIGATIONS

Pursuant to the terms of the Facility Agreement, a lender will not be obliged to fund a utilisation (except for a rollover loan), and if the Majority Lenders (as defined in the Facility Agreement) so require and upon not less than 20 business days’ prior written notice to the Company, the facility agent shall cancel the available facility under the Facility Agreement and declare all loans, together with accrued interest and all other amounts accrued or outstanding under the finance documents immediately due and payable, in the occurrence of any of the following events:

- (a) a change in the ownership of the Company such that Mr. Tse Ping and his family members (the “**Tse Ping Family**”), Ms. Cheng Cheung Ling, Ms. Tse, Theresa Y Y and her family members (the “**Tse Theresa Family**”) and Mr. Tse, Eric S Y and his family members (the “**Tse Eric Family**”) collectively cease to own (directly or indirectly) at least 35% of the issued share capital of the Company;
- (b) Mr. Tse Ping ceases to be a member of the board of directors (the “**Board**”) of the Company;
- (c) the role of Chairman of the Company is not taken by a member of the Tse Ping Family, the Tse Theresa Family or the Tse Eric Family; or
- (d) the Tse Ping Family, the Tse Theresa Family and the Tse Eric Family collectively cease to be the single largest shareholder of the Company.

The Company will continue to make relevant disclosure under its subsequent interim and annual reports pursuant to Rule 13.21 of the Listing Rules as long as circumstances giving rise to the obligations under Rule 13.18 of the Listing Rules continue to exist.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 1 December 2021

As at the date of this announcement, the Board comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.